MannKind Corporation Participating at Upcoming Conferences

WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be participating at upcoming conferences.

• 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 9:00 am (ET) at the Lotte New York Palace, New York, NY. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.
• BTIG MedTech, Life Science & Diagnostic Tools 2019 Conference February 26-28, 2019 in Snowbird, UT. Participating from the Company will be its Chief Financial Officer, Steven B. Binder, and Chief Commercial Officer, Patrick McCauley in one-on-one meetings connecting management with institutional investors.

About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
Rose Alinaya
SVP Investor Relations
818-661-5000
ir@mannkindcorp.com 

Source: MannKind Corporation